Anticancer Drugs Market Scope
Anticancer drug also known as antineoplastic drug. Any drug which is effective in the treatment of malignant, or tumorous diseases is known as anticancer drugs. The major classes of anticancer drugs comprises of alkylating agents, natural products, antimetabolites, and hormones. This drugs contains alkylating agents like ifosfamide, cyclophosphamide, melphalan, and others. This drugs are used to kill proliferating cancer cells. Spread of cancer is mainly occur by the rapid outburst of abnormal cells apart from their boundaries. This abnormal cells invades adjoining organs. Changing lifestyle, rising number of geriatric population leads to rise in prevalence of cancer across the globe. According to study, 2.3 million cases of cancer was estimated in 2020. Majorly lung, breast and colorectal cancer contributed to the new incidence cases. Thus, with rising incidence cases, the demand for anticancer drugs has been raised. Governments & research organisations across the globe are focusing to spread awareness regarding cancer treatments majorly in African countries. Thus, pharmaceutical companies are focusing on providing new products lines for the treatment of advanced cancers which is anticipated to drive the market growth over forecast period.
The Anticancer Drugs market study is segmented, by Application (Hospitals & Clinics and Oncological Research Centres) and major geographies with country level break-up.
Novartis AG (Switzerland), Bristol-Myers Squibb (United States), Johnson & Johnson (United States), Pfizer Inc. (United States), Merck & Co., Inc. (United States), Hoffmann-La Roche Ltd. (United States), Astra Zeneca (United Kingdom), AbbVie Inc. (United States), Celgene (United States), Eli Lilly & Co (United States), Cadila Healthcare Limited (India), Dr. Reddy’s Laboratories Ltd. (India) and LOGENEX Pharm GmbH (Germany) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Shilpa Therapeutics Pvt. Ltd (India), Amgen (United States) and AQVIDA GmbH (Germany).
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
AdvanceMarketAnalytics has segmented the market of Global Anticancer Drugs market by Type, Application and Region.
On the basis of geography, the market of Anticancer Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Market Leaders and their expansionary development strategies
In December 2019, Merck & Co. has acquired ArQule Inc. ArQule Inc is mainly developing kinases inhibitors. This acquisition was valued at USD 2.7 billion. Through this acquisition, company is able to expands its anticancer drugs portfolio., and In December 2019, Sanofi completed acquisition of Synthorx Inc. Synthorx Inc is manufacturers of immunotherapies. This acquisition was valued at USD2.5 billion. With this acquisition, company has strengthen its immunotherapy offerings.
In April 2020, Shilpa Medicare Ltd. has launched generic version of cancer drug Dasatinib. Dasashil revolutionise version which offers the treatment by ensuring availability of therapy to Indian patients. With this new launch, company is able to provide generic version which have huge affordability for patients.
BLA- A biologics license application (BLA) is defined by the U.S. Food and Drug Administration (FDA). It is regulated under 21 CFR 600 – 680. The biologics license application is a permission to introduce, a biologic product into interstate commerce (21 CFR 601.2).
- Pharmaceutical Companies Conducting Massive R&D Activities for Development of the New Product Lines to Treat Advanced Cancers
- Growing Expenditure of Pharmaceutical Industry
- Increasing Cancer Incidence across the Globe
- Rising Government Initiatives to Increase Awareness Regarding Advanced Treatments
- Government Funding’s For Oncological Research Centers to Develop Novel Drugs
- Rising Approvals for Anticancer Drugs to Advanced Cancer Has Created Growth Opportunities for Market
- Huge Treatment Cost of Advanced Cancer May Restrain Its Demand
- Side Effects Associated With Anti-Cancer Drugs Expected To Hamper Its Demand
- Huge Requirement of Investments for Drug Developments
Key Target Audience
Anti-Cancer Drugs Manufacturers/Suppliers/Distributor, Raw Material Suppliers, Oncological Research Centers, New Entrants/Investors, Strategic Business Planners, Governments and End Use Industry
Frequently asked questions:1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.2. How big is the Anticancer Drugs Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.